Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "therapies"

1241 News Found

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
Clinical Trials | October 13, 2025

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma


Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
People | October 13, 2025

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026


Cadila launches allergy relief tablet Dlorfast-M
News | October 13, 2025

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


Samsung Biologics introduces optimized manufacturing framework ‘ExellenS’
News | October 12, 2025

Samsung Biologics introduces optimized manufacturing framework ‘ExellenS’

ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed


Dr. Jitendra Singh inaugurates 10th Annual
Biotech | October 11, 2025

Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium

Several technologies for hemoglobinopathies are being transferred to commercial partners


Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors
News | October 10, 2025

Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors

First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors


Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US
News | October 10, 2025

Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US

The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision


Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra
News | October 08, 2025

Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra

Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025


RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia
News | October 08, 2025

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months